Scinai Immunotherapeutics Ltd. (SCNI) Fair Value 2026

SCNI · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (50/100)

Quick Summary — As of 2026-08-31, Scinai Immunotherapeutics Ltd. (SCNI) trades at $2.50, versus a $9.25 median fair value across its 2 active models — 270.1% above the current price. QOC: 5.6/10. Value Trap Risk: 50/100 (WARN). 2/13 models active.

Key Facts

Ticker
SCNI
Price
$2.50
Quality Score
5.6/10
Value Trap Risk
50/100
Models Active
2/13
Last Updated
Strength: ML-RIV suggests +348.3% upside with 57% confidence
Risk: Value Trap score of 50 suggests caution despite apparent undervaluation

Is Scinai Immunotherapeutics Ltd. (SCNI) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Scinai Immunotherapeutics Ltd. (SCNI) appears undervalued as of : the median of 2 independent fair value estimates is $9.25, 270.1% above the current price of $2.50. Estimates range from $7.30 to $11.21. SCNI scores 5.6/10 on fundamental quality and 50/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.1% versus its own 13-model consensus, across 3,804 rated companies as of 2026-08-31. SCNI’s +270.1% gap is wider than that market norm, and the Biotechnology sector median is -63.9%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Scinai Immunotherapeutics Ltd. Stock in 2026? →

What Fair Value Does Each Model Give SCNI?

2 Intrinsic Value Models vs. Current Price ($2.50)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $11.21 +348.3%
Option-Based · Medium Conviction
 $7.30 +191.9%

All Models Active

All 2 models are displayed above.

What Is Scinai Immunotherapeutics Ltd. (SCNI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Scinai Immunotherapeutics Ltd.'s intrinsic value is estimated at a median fair value of $9.25. At a current market price of $2.50, 2 of 2 active valuation models identify upside potential, projecting a median implied return of +270.1%. Notably, ML-RIV sees the most upside at +348.3% (fair value: $11.21), while PWERM is the most conservative at +191.9% ($7.30). The spread between these extremes — +156.4% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About SCNI?

2 of 13 models are currently active for SCNI. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for SCNI is $9.25 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does SCNI Rank in Biotechnology?

Among 625 Biotechnology stocks, SCNI ranks #202 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Scinai Immunotherapeutics Ltd. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating SCNI should weigh these sector-specific dynamics alongside our model-derived fair values.

Is SCNI a Value Trap?

CirclFi's Value Trap algorithm assigns SCNI a score of 50/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Scinai Immunotherapeutics Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Scinai Immunotherapeutics Ltd.'s fundamental quality profile registers 5.6/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +156.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SCNI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SCNI's 2 active models, average confidence is 44%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Scinai Immunotherapeutics Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ALTAltimmune, Inc.QOC 5.6ACETAdicet Bio, Inc.QOC 5.6FATEFate Therapeutics, Inc.QOC 5.6KYNBKyntra Bio, Inc.QOC 5.6CYCNCyclerion Therapeutics, Inc.QOC 5.6IVVDInvivyd, Inc.QOC 5.6PGENPrecigen, Inc.QOC 4.9RNTXRein Therapeutics Inc.QOC 4.2MRNAModerna, Inc.QOC 7.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ALT · ACET · FATE · KYNB · CYCN · IVVD · PGEN · RNTX · MRNA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SCNI?

5 companies across all industries closest to SCNI’s Quality of Company score of 5.6/10.

RRGBRed Robin Gourmet Burgers, Inc.QOC 5.6PACBPacific Biosciences of California, Inc.QOC 5.6LUCKLucky Strike Entertainment CorporationQOC 5.6COCHEnvoy Medical, Inc.QOC 5.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RRGB · PACB · LUCK · COCH · NVDA

Where Does SCNI Sit in CirclFi's Biotechnology Rankings?

SCNI is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Scinai Immunotherapeutics Ltd.’s Valuation?

What is Scinai Immunotherapeutics Ltd.'s intrinsic value in 2026?

CirclFi puts Scinai Immunotherapeutics Ltd. (SCNI)'s intrinsic value at $9.25 — the median of 2 independent model estimates as of 2026-08-31, ranging from $7.30 to $11.21. The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SCNI overvalued or undervalued right now?

At $2.50, 2 of 2 active models suggest SCNI may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $9.25, 270.1% above the current price of $2.50 — a consensus view that SCNI is undervalued. The assessment depends on which methodology best fits Scinai Immunotherapeutics Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 5.6 mean for SCNI?

Scinai Immunotherapeutics Ltd.'s QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SCNI?

CirclFi analyzes SCNI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is SCNI a value trap in 2026?

Scinai Immunotherapeutics Ltd.'s Value Trap score is 50/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Scinai Immunotherapeutics Ltd. (SCNI) has a median fair value of $9.25 — 270.1% above the current price of $2.50 — as of 2026-08-31.” Source: circlfi.com/stock/SCNI/ · Methodology
Primary sources for this SCNI valuation
  • Financial statements: Scinai Immunotherapeutics Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001611747) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SCNI as of ; valuations recomputed .